Follow
Kate Marie Lewis
Kate Marie Lewis
Centre for Neurological Diseases, The University of Adelaide
Verified email at adelaide.edu
Title
Cited by
Cited by
Year
Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood–brain barrier during extravasation and brain invasion
KM Lewis, E Harford-Wright, R Vink, AJ Nimmo, MN Ghabriel
Clinical & experimental metastasis 30, 1-12, 2013
362013
Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors
E Harford-Wright, KM Lewis, MN Ghabriel, R Vink
PloS one 9 (5), e97002, 2014
322014
Blocking neurogenic inflammation for the treatment of acute disorders of the central nervous system
KM Lewis, RJ Turner, R Vink
International journal of inflammation 2013, 2013
312013
Towards drug discovery for brain tumours: interaction of kinins and tumours at the blood brain barrier interface
E Harford-Wright, K M Lewis, R Vink
Recent Patents on CNS Drug Discovery (Discontinued) 6 (1), 31-40, 2011
292011
Evaluating the role of substance P in the growth of brain tumors
E Harford-Wright, KM Lewis, R Vink, MN Ghabriel
Neuroscience 261, 85-94, 2014
272014
Asymmetric cell division: implications for glioma development and treatment
K Lewis, C Petritsch
Translational neuroscience 4 (4), 484-503, 2013
212013
NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer
KM Lewis, E Harford-Wright, R Vink, MN Ghabriel
Anti-cancer drugs 24 (4), 344-354, 2013
202013
Characterisation of Walker 256 breast carcinoma cells from two tumour cell banks as assessed using two models of secondary brain tumours
KM Lewis, E Harford-Wright, R Vink, MN Ghabriel
Cancer cell international 13, 1-12, 2013
182013
Targeting classical but not neurogenic inflammation reduces peritumoral oedema in secondary brain tumours
KM Lewis, E Harford-Wright, R Vink, MN Ghabriel
Journal of Neuroimmunology 250 (1-2), 59-65, 2012
122012
Self-service healthcare platform
KM Lewis, S Shekhar, F Jamshidian, TA Tusing
US Patent App. 15/644,691, 2018
82018
The potential for substance P antagonists as anti-cancer agents in brain tumours
E Harford-Wright, K M Lewis, R Vink
Recent Patents on CNS Drug Discovery (Discontinued) 8 (1), 13-23, 2013
82013
Advancing drug therapy for brain tumours: A current review of the pro-inflammatory peptide substance P and its antagonists as anti-cancer agents
K Mander, E Harford-Wright, K M Lewis, R Vink
Recent Patents on CNS Drug Discovery (Discontinued) 9 (2), 110-121, 2014
72014
Entity cohort discovery and entity profiling
JA Caballero, AC Yarlagadda, F Jamshidian, KM Lewis, EMG Cadag, ...
US Patent App. 14/990,766, 2016
42016
Divergent effects of BRAF activation in neural stem and progenitor-like glioblastoma cells
RG Lerner, Y Ihara, K Lewis, A Griveau, B Reichhold, D Qu, M McMahon, ...
Cancer Research 74 (19_Supplement), 1944-1944, 2014
2014
STEM-AND PROGENITOR-LIKE CELL CONTRIBUTION TO MALIGNANT ASTROCYTOMA HETEROGENEITY
C Petritsch, R Lerner, K Lewis, N Andor, T Ozawa, Y Yoshida, ...
Neuro-oncology 16 (suppl_3), iii21-iii21, 2014
2014
Treatment with the NK1 Antagonist Emend Reduces Blood Brain Barrier Dysfunction and Edema
E Harford-Wright, KM Lewis, MN Ghabriel, R Vink
2014
The role of substance P in the progression and complications of secondary brain tumours.
K Lewis
2012
The system can't perform the operation now. Try again later.
Articles 1–17